Clinical Physiology of Circulation

ISSN 1814-6910 (Print)
ISSN 2410-9134 (Online)

 

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery


Issue's catalogue ➤ КФК. 2025; 22 (3): 199-286 ➤ Влияние различной локализации злокачественных новообразований на течение и лечение ишемической болезни сердца

The influence of different localizations of malignant neoplasms on the course and treatment of coronary heart disease

Authors: Rakhmanzhanov A.A., Asymbekova E.U., Golubev E.P., Tugeeva E.F., Borbodoeva B.M., Akhmedov D.R., Sherstyannikova O.M., Buziashvili Yu.I. T.

Company:
Bakoulev National Medical Research Center for Cardiovascular Surgery, Moscow, Russian Federation

E-mail: Сведения доступны для зарегистрированных пользователей.

DOI: https://doi.org/10.24022/1814-6910-2025-22-3-261-273

UDC: 616-006:616.12-008.64

Link: Clinical Physiology of Blood Circulaiton. 2025; 22 (3): 261-273

Quote as: Rakhmanzhanov A.A., Asymbekova E.U., Golubev E.P., Tugeeva E.F., Borbodoeva B.M., Akhmedov D.R., Sherstyannikova O.M., Buziashvili Yu.I. The influence of different localizations of malignant neoplasms on the course and treatment of coronary heart disease. Clinical Physiology of Сirculation. 2025; 22 (3): 261–273 (in Russ.). DOI: 10.24022/1814-6910-2025-22-3-261-273

Keywords:  coronary heart disease malignant neoplasms coronary artery bypass grafting percutaneous coronary intervention comorbidity cardioncology

Received / Accepted:  18.08.2025 / 15.09.2025

Full text:
Subscribe 🔒

Abstract

Objective. Studies in 13 countries have revealed an association between malignant neoplasms (ZN) and an increased risk of cardiovascular diseases (CVD). Assessment of the effect of different localization of malignant neoplasm on the course of coronary heart disease, treatment tactics and outcomes.

Material and methods. 136 patients with coronary artery disease and coronary artery disease who underwent myocardial revascularization were examined. The study identified groups of patients with coronary heart disease and malignant tumors of various localization: gastrointestinal tract (GIT), respiratory organs (RO), endocrine organs (EO) and urinary system (US). The clinical parameters, medical history, the nature of coronary artery damage, methods and complications of myocardial revascularization, as well as the treatment features of oncopathology were analyzed.

Results. Patients with EO were older (73.6 years old), with a high incidence of obesity, hyperlipidemia, and aggravated heredity. Smoking, hypertension, and physical inactivity were common in all groups. The function of the left ventricle was normal, but patients with gastrointestinal tumors had a slightly decreased LVEF. In terms of coronary artery damage, a significant difference was observed in the lesion of the envelope branch of the LCA – it was much less common in MVS tumors. The choice of the revascularization method depended on the location of the tumor: PCI and CABG were used approximately equally for gastrointestinal tumors, and PCI was mainly performed for tumors of the endocrine organs and US. The incidence of complications after myocardial revascularization was highest in patients with gastrointestinal (22.5%) and RO (19.8%) tumors and significantly lower in patients with EO (3.6%) and US (4.7%) tumors. Complications in the gastrointestinal tract group are mainly associated with surgical treatment.

Conclusion. Localization of the malignant neoplasm has a significant impact on the course of coronary heart disease and the choice of treatment method. Surgical revascularization was more often used for gastrointestinal tumors, while endovascular treatment was mainly used for endocrine and urinary tumors. Tumor localization is associated with the risk of complications after myocardial revascularization – with gastrointestinal and RO tumors, complications are more common. The results emphasize the need for an individual approach to patients with cardioncological pathology, which will improve treatment outcomes.

References

  1. Liu S., Li Y., Zeng X. et al. Burden of Cardiovascular Diseases in China, 1990–2016: Findings From the 2016 Global Burden of Disease Study. JAMA Cardiol. 2019; 4 (4): 342–352. DOI: 10.1001/jamacardio.2019.0295
  2. Townsend N., Kazakiewicz D., Lucy Wright F., Timmis A., Huculeci R., Torbica A. et al. Epidemiology of cardiovascular disease in Europe. Nat. Rev. Cardiol. 2022; 19 (2): 133–143. DOI: 10.1038/s41569-021-00607-3
  3. Marquina C., Talic S., Vargas-Torres S., Petrova M., Abushanab D., Owen A. et al. Future burden of cardiovascular disease in Australia: impact on health and economic outcomes between 2020 and 2029. Eur. J. Prev. Cardiol. 2022; 29 (8): 1212–1219. DOI: 10.1093/eurjpc/zwab001
  4. Andersson C., Vasan R.S. Epidemiology of cardiovascular disease in young individuals. Nat. Rev. Cardiol. 2018; 15 (4): 230–240. DOI: 10.1038/nrcardio.2017.154
  5. Mensah G.A., Fuster V., Murray C.J.L., Roth G.A.; Global Burden of Cardiovascular Diseases and Risks Collaborators. Global Burden of Cardiovascular Diseases and Risks, 1990–2022. J. Am. Coll. Cardiol. 2023; 82 (25): 2350–2473. DOI: 10.1016/j.jacc.2023.11.007
  6. Global Burden of Disease 2019 Cancer Collaboration, Kocarnik J.M., Compton K. et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019. JAMA Oncol. 2022; 8 (3): 420–444. DOI: 10.1001/jamaoncol.2021.6987
  7. Vogel B., Acevedo M., Appelman Y., Bairey Merz C.N., Chieffo A., Figtree G.A. et al. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. Lancet. 2021; 397 (10292): 2385–2438. DOI: 10.1016/S0140-6736(21)00684-X
  8. Li Q., Zhang G., Li X., Xu S., Wang H., Deng J. et al. Risk of cardiovascular disease among cancer survivors: systematic review and meta-analysis. EClinical Med. 2025; 84: 103274. DOI: 10.1016/j.eclinm.2025.103274
  9. Quintana R.A., Monlezun D.J., Davogustto G., Saenz H.R., Lozano-Ruiz F., Sueta D. et al. Outcomes following percutaneous coronary intervention in patients with cancer. Int. J. Cardiol. 2020; 300: 106–112. DOI: 10.1016/j.ijcard.2019.09.016
  10. Costa I.B.S.D.S., Andrade F.T.A., Carter D., Seleme V.B., Costa M.S., Campos C.M., Hajjar L.A. Challenges and Management of Acute Coronary Syndrome in Cancer Patients. Front. Cardiovasc. Med. 2021; 8: 590016. DOI: 10.3389/fcvm.2021.590016
  11. Raisi-Estabragh Z., Kobo O., Freeman P., Petersen S.E., Kolman L., Miller R.J.H. et al. Temporal trends in disease-specific causes of cardiovascular mortality amongst patients with cancer in the USA between 1999 and 2019. Eur. Heart J. Qual. Care Clin. Outcomes. 2022; 9 (1): 54–63. DOI: 10.1093/ehjqcco/qcac016
  12. Potts J.E., Iliescu C.A., Lopez Mattei J.C., Martinez S.C., Holmvang L., Ludman P. et al. Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States. Eur. Heart J. 2019; 40 (22): 1790–1800. DOI: 10.1093/ eurheartj/ehy769
  13. Leong D.P., Cirne F., Aghel N., Baro Vila R.C., Cavalli G.D. et al. Cardiac interventions in patients with active, advanced solid and hematologic malignancies: JACC: cardiooncology state-of-the-art review. JACC Cardiooncol. 2023; 5 (4): 415–430. DOI: 10.1016/j. jaccao.2023.05.008
  14. Комаров Р.Н., Новиков С.С., Осминин С.В., Билялов И.Р., Рябов К.Ю., Заваруев А.В. и др. Хирургия рака желудка у пациентов с конкурирующей ишемической болезнью сердца (клинические случаи). Российский онкологический журнал. 2021; 26 (6): 213–224. DOI: 10.17816/onco111771
  15. Han X.J., Li J.Q., Khannanova Z., Li Y. Optimal management of coronary artery disease in cancer patients. Chronic. Dis. Transl. Med. 2020; 5 (4): 221–233. DOI: 10.1016/j.cdtm.2019.12.007
  16. Алекян Б.Г., Бойцов С.А., Маношкина Е.М., Ганюков В.И. Динамика реваскуляризации в РФ за 2016–2020 гг. Кардиология. 2021; 61 (12): 4–15. DOI: 10.18087/cardio.2021.12.n1879
  17. Бузиашвили Ю.И., Асымбекова Э.У., Иошина В.И., Кокшенева И.В. Результаты лечебной и научной работы клинико- диагностического отделения за 2023 год. Сердечно-сосудистые заболевания. Бюллетень НЦССХ им. А.Н. Бакулева РАМН. 2024; 25 (5): 504–514. DOI: 10.24022/1810-0694-2024-25-5-504-514
  18. Желихажева М.В., Батуков И.А., Мерзляков В.Ю. Значение реваскуляризации миокарда у пациентов с ишемической болезнью сердца и сопутствующей онкологической патологией. Сердечно-сосудистые заболевания. Бюллетень НЦССХ им. А.Н. Бакулева РАМН. 2020; 21 (4): 362–371. DOI: 10.24022/1810-0694-2020-21-4-362-371
  19. Никитина Т.Г., Домбровский М.М., Алекян Б.Г. и др. Стентирование коронарных артерий у больных с ишемической болезнью сердца и онкопатологией. Креативная кардиология. 2016; 10 (4): 296–305. DOI: 10.15275/kreatkard.2016.04.04
  20. Голухова Е.З. Отчет о лечебной и научной работе Национального медицинского исследовательского центра сердечно- сосудистой хирургии им. А.Н. Бакулева Минздрава России за 2024 год. Перспективы дальнейшего развития. Сердечно- сосудистые заболевания. Бюллетень НЦССХ им. А.Н. Бакулева РАМН. 2025; 26 (спецвыпуск): 5–130. DOI: 10.24022/1810-0694-2025-26S
****
  1. Liu S., Li Y., Zeng X. et al. Burden of Cardiovascular Diseases in China, 1990–2016: Findings From the 2016 Global Burden of Disease Study. JAMA Cardiol. 2019; 4 (4): 342–352. DOI: 10.1001/jamacardio.2019.0295
  2. Townsend N., Kazakiewicz D., Lucy Wright F., Timmis A., Huculeci R., Torbica A. et al. Epidemiology of cardiovascular disease in Europe. Nat. Rev. Cardiol. 2022; 19 (2): 133–143. DOI: 10.1038/s41569-021-00607-3
  3. Marquina C., Talic S., Vargas-Torres S., Petrova M., Abushanab D., Owen A. et al. Future burden of cardiovascular disease in Australia: impact on health and economic outcomes between 2020 and 2029. Eur. J. Prev. Cardiol. 2022; 29 (8): 1212–1219. DOI: 10.1093/eurjpc/zwab001
  4. Andersson C., Vasan R.S. Epidemiology of cardiovascular disease in young individuals. Nat. Rev. Cardiol. 2018; 15 (4): 230–240. DOI: 10.1038/nrcardio.2017.154
  5. Mensah G.A., Fuster V., Murray C.J.L., Roth G.A.; Global Burden of Cardiovascular Diseases and Risks Collaborators. Global Burden of Cardiovascular Diseases and Risks, 1990–2022. J. Am. Coll. Cardiol. 2023; 82 (25): 2350–2473. DOI: 10.1016/j.jacc.2023.11.007
  6. Global Burden of Disease 2019 Cancer Collaboration, Kocarnik J.M., Compton K. et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019. JAMA Oncol. 2022; 8 (3): 420–444. DOI: 10.1001/jamaoncol.2021.6987
  7. Vogel B., Acevedo M., Appelman Y., Bairey Merz C.N., Chieffo A., Figtree G.A. et al. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. Lancet. 2021; 397 (10292): 2385–2438. DOI: 10.1016/S0140-6736(21)00684-X
  8. Li Q., Zhang G., Li X., Xu S., Wang H., Deng J. et al. Risk of cardiovascular disease among cancer survivors: systematic review and meta-analysis. EClinical Med. 2025; 84: 103274. DOI: 10.1016/j.eclinm.2025.103274
  9. Quintana R.A., Monlezun D.J., Davogustto G., Saenz H.R., Lozano-Ruiz F., Sueta D. et al. Outcomes following percutaneous coronary intervention in patients with cancer. Int. J. Cardiol. 2020; 300: 106–112. DOI: 10.1016/j.ijcard.2019.09.016
  10. Costa I.B.S.D.S., Andrade F.T.A., Carter D., Seleme V.B., Costa M.S., Campos C.M., Hajjar L.A. Challenges and Management of Acute Coronary Syndrome in Cancer Patients. Front. Cardiovasc. Med. 2021; 8: 590016. DOI: 10.3389/fcvm.2021.590016
  11. Raisi-Estabragh Z., Kobo O., Freeman P., Petersen S.E., Kolman L., Miller R.J.H. et al. Temporal trends in disease-specific causes of cardiovascular mortality amongst patients with cancer in the USA between 1999 and 2019. Eur. Heart J. Qual. Care Clin. Outcomes. 2022; 9 (1): 54–63. DOI: 10.1093/ehjqcco/qcac016
  12. Potts J.E., Iliescu C.A., Lopez Mattei J.C., Martinez S.C., Holmvang L., Ludman P. et al. Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States. Eur. Heart J. 2019; 40 (22): 1790–1800. DOI: 10.1093/eurheartj/ehy769
  13. Leong D.P., Cirne F., Aghel N., Baro Vila R.C., Cavalli G.D. et al. Cardiac interventions in patients with active, advanced solid and hematologic malignancies: JACC: cardiooncology state-of-the-art review. JACC Cardiooncol. 2023; 5 (4): 415–430. DOI: 10.1016/j.jaccao.2023.05.008
  14. Komarov R.N., Novikov S.S., Osminin S.V., Bilyalov I.R., Ryabov K.Yu., Zavaruyev A.V. et al. Gastric cancer surgery in patients with concurrent coronary artery disease (clinical cases). Russian Journal of Oncology. 2021; 26 (6): 213–224 (in Russ.). DOI: 10.17816/onco111771
  15. Han X.J., Li J.Q., Khannanova Z., Li Y. Optimal management of coronary artery disease in cancer patients. Chronic. Dis. Transl. Med. 2020; 5 (4): 221–233. DOI: 10.1016/j.cdtm.2019.12.007
  16. Alekyan B.G., Boytsov S.A., Manoshkina Ye.M., Ganyukov V.I. Dynamics of revascularization in the Russian Federation for 2016– 2020. Kardiologiya. 2021; 61 (12): 4–15 (in Russ.). DOI: 10.18087/cardio.2021.12.n1879
  17. Buziashvili Yu.I., Asymbekova E.U., Ioshina V.I., Koksheneva I.V. Results of the clinical and scientific work of the clinical diagnostic department for 2023. The Bulletin of Bakoulev Center. Cardiovascular Diseases. 2024; 25 (5): 504–514 (in Russ.). DOI: 10.24022/1810-0694-2024-25-5-504-514
  18. Zhelikhazheva M.V., Batukov I.A., Merzlyakov V.Yu. The importance of myocardial revascularization in patients with coronary heart disease and concomitant oncological pathology. The Bulletin of Bakoulev Center. Cardiovascular Diseases. 2020; 21 (4): 362–371 (in Russ.). DOI: 10.24022/1810-0694-2020-21-4-362-371
  19. Nikitina T.G., Dombrovskiy M.M., Alekyan B.G. et al. Stenting of coronary arteries in patients with coronary heart disease and oncopathology. Creative Cardiology. 2016; 10 (4): 296–305 (in Russ.). DOI: 10.15275/kreatkard.2016.04.04
  20. Golukhova Ye.Z. Report on the medical and scientific work of The Bulletin of Bakoulev Center. Cardiovascular Diseases. 2025; 26 (Special Issue): 5–130 (in Russ.). DOI: 10.24022/1810-0694-2025-26S

About Authors

  • Aliyer A. Rakhmanzhanov, Junior Researcher Assistant; ORCID
  • Elmira U. Asymbekova, Dr. Med. Sci., Leading Researcher, Cardiologist; ORCID
  • Evgeny P. Golubev, Cand. Med. Sci., Senior Researcher; ORCID
  • Elvina F. Tugeeva, Dr. Med. Sci., Senior Researcher; ORCID
  • Baktygul M. Borbodoeva, Cand. Med. Sci., Researcher, Cardiologist; ORCID
  • Daniyal R. Akhmedov, Junior Researcher; ORCID
  • Olga M. Sherstyannikova, Cand. Med. Sci., Researcher, Cardiologist; ORCID
  • Yuri I. Buziashvili, Dr. Med. Sci., Professor, Academician of the Russian Academy of Sciences, Head of the Clinical and Diagnostic Department; ORCID

 If you found mistakes, select text and press Alt+A